A Phase I Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2017
At a glance
- Drugs TAS 303 (Primary)
- Indications Stress incontinence
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 09 Aug 2016 Status changed from recruiting to completed.
- 28 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 05 Oct 2015 New trial record